LHC Group (LHCG) Stock Rating Reaffirmed by William Blair

LHC Group (NASDAQ:LHCG)‘s stock had its “buy” rating reiterated by equities researchers at William Blair in a report released on Thursday.

Other research analysts have also recently issued reports about the stock. SunTrust Banks lifted their target price on shares of LHC Group to $115.00 and gave the stock a “buy” rating in a report on Thursday, September 13th. Jefferies Financial Group lifted their target price on shares of LHC Group to $120.00 and gave the stock a “buy” rating in a report on Friday, August 3rd. BidaskClub cut shares of LHC Group from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 10th. Benchmark set a $110.00 price objective on shares of LHC Group and gave the company a “buy” rating in a report on Thursday, August 2nd. Finally, Bank of America set a $119.00 price objective on shares of LHC Group and gave the company a “buy” rating in a report on Tuesday, September 18th. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $103.00.

LHC Group stock traded down $4.55 during trading hours on Thursday, hitting $86.88. The stock had a trading volume of 90,374 shares, compared to its average volume of 346,690. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.59 and a current ratio of 1.59. The stock has a market capitalization of $2.80 billion, a PE ratio of 35.90, a price-to-earnings-growth ratio of 1.40 and a beta of 0.52. LHC Group has a 12-month low of $58.65 and a 12-month high of $103.79.

LHC Group (NASDAQ:LHCG) last issued its earnings results on Wednesday, October 31st. The health services provider reported $0.95 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.95. The business had revenue of $507.00 million during the quarter, compared to analysts’ expectations of $515.03 million. LHC Group had a net margin of 3.75% and a return on equity of 8.33%. The business’s revenue for the quarter was up 88.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.64 earnings per share. As a group, equities research analysts forecast that LHC Group will post 3.52 EPS for the current fiscal year.

In other news, SVP Jeff Reibel sold 1,921 shares of the business’s stock in a transaction that occurred on Monday, August 20th. The shares were sold at an average price of $94.12, for a total transaction of $180,804.52. Following the completion of the transaction, the senior vice president now directly owns 8,125 shares of the company’s stock, valued at $764,725. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Donald Dwayne Stelly sold 2,756 shares of the business’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $99.32, for a total transaction of $273,725.92. Following the transaction, the chief operating officer now directly owns 104,512 shares of the company’s stock, valued at $10,380,131.84. The disclosure for this sale can be found here. 6.80% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Voya Investment Management LLC raised its holdings in shares of LHC Group by 65.9% during the second quarter. Voya Investment Management LLC now owns 11,818 shares of the health services provider’s stock valued at $1,012,000 after purchasing an additional 4,694 shares during the last quarter. Alps Advisors Inc. purchased a new stake in LHC Group during the second quarter valued at approximately $442,000. FMR LLC increased its holdings in LHC Group by 297.8% during the second quarter. FMR LLC now owns 1,151,406 shares of the health services provider’s stock valued at $98,548,000 after buying an additional 861,952 shares during the last quarter. Waddell & Reed Financial Inc. increased its holdings in LHC Group by 4.6% during the second quarter. Waddell & Reed Financial Inc. now owns 526,400 shares of the health services provider’s stock valued at $45,055,000 after buying an additional 23,200 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in LHC Group by 71.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 193,202 shares of the health services provider’s stock valued at $16,537,000 after buying an additional 80,518 shares during the last quarter. 86.24% of the stock is owned by hedge funds and other institutional investors.

About LHC Group

LHC Group, Inc, a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company operates through four segments: Home Health Services, Hospice Services, Community-Based Services, and Facility-Based Services. The Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services.

See Also: How to Invest in a Bull Market

Analyst Recommendations for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply